Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8221 to 8235 of 9025 results

  1. Durvalumab for treating recurrent or metastatic squamous cell head and neck cancer after platinum-based chemotherapy [ID1231]

    Discontinued Reference number: GID-TA10473

    Technology appraisal guidance
    Discontinued

  2. Bevacizumab for treating recurrent glioblastoma [ID978]

    Discontinued Reference number: GID-TA10149

    Technology appraisal guidance
    Discontinued

  3. Nivolumab in combination with platinum-doublet chemotherapy for untreated non-small-cell lung cancer [ID1135]

    Discontinued Reference number: GID-TA10233

    Technology appraisal guidance
    Discontinued

  4. Venetoclax with ibrutinib and obinutuzumab for untreated chronic lymphocytic leukaemia ID1270

    Discontinued Reference number: GID-TA10211

    Technology appraisal guidance
    Discontinued

  5. Masitinib for treating malignant melanoma that has a c-Kit juxtamembrane mutation [ID1082]

    Discontinued Reference number: GID-TA10627

    Technology appraisal guidance
    Discontinued

  6. Sunitinib in combination with a taxane for the first line treatment of advanced and/or metastatic breast cancer [ID58]

    Discontinued Reference number: GID-TAG391

    Technology appraisal guidance
    Discontinued

  7. Rociletinib for previously treated EGFR T790M-positive metastatic non-small-cell lung cancer [ID883]

    Discontinued Reference number: GID-TA10045

    Technology appraisal guidance
    Discontinued

  8. L-glutamine for preventing painful crises in sickle cell disease in people aged 5 years and over [ID1523]

    Discontinued Reference number: GID-TA10452

    Technology appraisal guidance
    Discontinued

  9. Ofatumumab (Arzerra) in combination with chemotherapy for follicular lymphoma; second line - refractory to rituximab [ID1487]

    Discontinued Reference number: GID-TA10437

    Technology appraisal guidance
    Discontinued

  10. Laquinimod for treating relapsing-remitting multiple sclerosis [ID560]

    Discontinued Reference number: GID-TAG337

    Technology appraisal guidance
    Discontinued

  11. Lorcaserin hydrochloride for the treatment of obesity and overweight [ID337]

    Discontinued Reference number: GID-TAG420

    Technology appraisal guidance
    Discontinued

  12. Tralokinumab for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3823]

    Discontinued Reference number: GID-TA10702

    Technology appraisal guidance
    Discontinued

  13. Pertuzumab for untreated metastatic HER2-positive gastric or gastro-oesophageal junction cancer [ID1096]

    Discontinued Reference number: GID-TA10159

    Technology appraisal guidance
    Discontinued

  14. Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma [ID3975]

    In development Reference number: GID-TA10858 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Infigratinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement [ID3992]

    In development Reference number: GID-TA10882 Expected publication date: TBC

    Technology appraisal guidance
    In development